News
-
-
-
COMMUNIQUÉ DE PRESSE
Verisante Technology, Inc. Announces RTO Update:
SunRegen Healthcare AG closes $2.1 million private placement, advancing towards RTO with Verisante. SunRegen focuses on developing neurodegenerative drugs, starting with compound SBC003. Verisante to acquire 100% interest in SunRegen, aiming to qualify as Tier 2 Life Sciences Issuer -
-
-
-
-
-
-